Indication · General & Plastic Surgery
Hair loss
Last checked: Nov 21, 2026Source: FDA, ClinicalTrials.gov
Devices
99
Cleared or approved since 2000
PMA and De Novo
0
Higher-risk or first-of-kind devices
Breakthrough devices
0
Authorized through June 30, 2026
Recruiting device trials
19
126 device trials in all
Devices
0 devices via De Novo. PMA and De Novo devices first, then devices with the most FDA decisions. Each opens a full summary.
No devices on this pathway.
Device trials
Device studies on ClinicalTrials.gov for this condition, any status, newest update first.
- SCALp Cooling for pReventing aLopecia With nEw anTibody-drug ConjugatesPivotal-lookingRecruiting
Jules Bordet InstituteAcademic, hospital or other
NCT07474558 · 102 participants (planned) · Start Oct 23, 2026 · Primary completion Jan 15, 2030
Device: scalp cooling · For: Advanced or Metastatic Solid Tumour; Antibody-Drug Conjugate; Alopecia
Sites: Anderlecht, Belgium; Mons, Belgium; Namur, Belgium
125 more trials with a free account
Device types
FDA product codes mapped to this indication. The mapping was made with AI help and may include a few loose fits.
Research
- Device studies on androgenetic alopecia across PubMed, Europe PMC and OpenAlex
- PubMed ↗
- Google Scholar ↗
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.